Johan van der Schoot

Mr. Johan van der Schoot

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2023 in Science Immunology
Verified
Journal Article
Closed access
MGMandy van Gulijk
Mandy van Gulijk
AKAnneloes van Krimpen
Anneloes van Krimpen
SSSjoerd T.T. Schetters
Sjoerd T.T. Schetters
MEMike Eterman
Mike Eterman
MEMarit J. van Elsas
Marit J. van Elsas
THThorbald van Hall
Thorbald van Hall
Despite the clinical success of immune checkpoint blockade (ICB), in certain cancer types, most patients with cancer do not respond well. Furthermore, in patients for whom ICB is initially successful, this is often short-lived because of the development of resistance to ICB. The mechanisms underlying primary or secondary ICB resistance are incompletely understood. Here, we identified preferential activation and enhanced suppressive capacity of regulatory T cells (T reg cells) in αPD-L1 therapy–resistant solid tumor–bearing mice. T reg cell depletion reversed resistance to αPD-L1 with concomitant expansion of effector T cells. Moreover, we found that tumor-infiltrating T reg cells in human patients with skin cancer, and in patients with non–small cell lung cancer, up-regulated a suppressive transcriptional gene program after ICB treatment, which correlated with lack of treatment response. αPD-1/PD-L1–induced PD-1 + T reg cell activation was also seen in peripheral blood of patients with lung cancer and mesothelioma, especially in nonresponders. Together, these data reveal that treatment with αPD-1 and αPD-L1 unleashes the immunosuppressive role of T reg cells, resulting in therapy resistance, suggesting that T reg cell targeting is an important adjunct strategy to enhance therapeutic efficacy.

2 August 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
JSJohan van der Schoot
Johan van der Schoot
FFFelix L. Fennemann
Felix L. Fennemann
MVMichael Valente
Michael Valente
YDYusuf Dolen
Yusuf Dolen
IHIris M. Hagemans
Iris M. Hagemans
FSFerenc A Scheeren
Ferenc A Scheeren
We develop a universal platform for CRISPR/HDR-engineering of hybridomas to obtain functionally diverse antibody panels.

12 May 2019 in Molecules
Verified
Journal Article
Open access
PDF file
LCLuis Cruz
Luis Cruz
PTPaul Tacken
Paul Tacken
JSJohan van der Schoot
Johan van der Schoot
FRFèlix Rueda
Fèlix Rueda
RTRuurd Torensma
Ruurd Torensma
CFCarl Figdor
Carl Figdor
Optimal targeting of nanoparticles (NP) to dendritic cells (DCs) receptors to deliver cancer-specific antigens is key to the efficient induction of anti-tumour immune responses. Poly (lactic-co-glycolic acid) (PLGA) nanoparticles containing tètanus toxoid and gp100 melanoma-associated antigen, toll-like receptor adjuvants were targeted to the DC-SIGN receptor in DCs by specific humanized antibodies or by ICAM3-Fc fusion proteins, which acts as the natural ligand. Despite higher binding and uptake efficacy of anti-DC-SIGN antibody-targeted NP vaccines than ICAM3-Fc ligand, no difference were observed in DC activation markers CD80, CD83, CD86 and CCR7 induced. DCs loaded with NP coated with ICAM3-Fc appeared more potent in activating T cells via cross-presentation than antibody-coated NP vaccines. This fact could be very crucial in the design of new cancer vaccines.

10 April 2019 in Preprints.org
Verified
Preprint
Open access
LCLuis J. Cruz
Luis J. Cruz
PTPaul J. Tacken
Paul J. Tacken
JSJohan van der Schoot
Johan van der Schoot
FRFelix Rueda
Felix Rueda
RTRuurd Torensma
Ruurd Torensma
CFCarl G. Figdor
Carl G. Figdor
Optimal targeting of nanoparticles (NP) to dendritic cells (DCs) receptors to deliver cancer-specific antigens is key to an efficient induction of anti-tumor immune responses. Poly (lactic-co-glycolic acid) (PLGA) nanoparticles containing tètanus toxoid and gp100 melanoma-associated antigen, toll-like receptor adjuvants were targeted to the DC-SIGN receptor in DCs by specific humanized antibodies or by ICAM3-Fc fusion proteins mimicking natural ligand. Despite higher binding and uptake efficacy of anti-DC-SIGN antibody-targeted NP vaccines than ICAM3-Fc ligand, no difference were observed in DC activation markers CD80, CD83, CD86 and CCR7 induced. DCs loaded with NP coated with ICAM3-Fc appeared more potent in activating T cells via cross-presentation than antibody-coated NP vaccines. This fact could be very crucial in the design of new cancer vaccines.

15 February 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
JSJohan van der Schoot
Johan van der Schoot
FFFelix L. Fennemann
Felix L. Fennemann
MVMichael Valente
Michael Valente
YDYusuf Dolen
Yusuf Dolen
IHIris M. Hagemans
Iris M. Hagemans
FSFerenc A Scheeren
Ferenc A Scheeren
Hybridoma technology is instrumental for the development of novel antibody therapeutics and diagnostics. Recent preclinical and clinical studies highlight the importance of antibody isotype for therapeutic efficacy. However, since the sequence encoding the constant domains is fixed, tuning antibody function in hybridomas has been restricted. Here, we demonstrate a versatile CRISPR/HDR platform to rapidly engineer the constant immunoglobulin domains to obtain recombinant hybridomas which secrete antibodies in the preferred format, species and isotype. Using this platform, we obtained recombinant hybridomas secreting Fab’ fragments, isotype switched chimeric antibodies, and Fc-silent mutants. These antibody products are stable, retain their antigen specificity, and display their intrinsic Fc-effector functions in vitro and in vivo. Furthermore, we can site-specifically attach cargo to these antibody products via chemo-enzymatic modification. We believe this versatile platform facilitates antibody engineering for the entire scientific community, empowering preclinical antibody research.One Sentence Summary: We demonstrate a universal CRISPR/HDR based platform for rapid genetic engineering of hybridomas to obtain functionally diverse antibody isotype panels in the species and format of choice.